STOCK TITAN

Spero Therapeuti - SPRO STOCK NEWS

Welcome to our dedicated page for Spero Therapeuti news (Ticker: SPRO), a resource for investors and traders seeking the latest updates and insights on Spero Therapeuti stock.

Spero Therapeutics, Inc. (SPRO) is a clinical-stage biopharmaceutical company pioneering novel therapies for multidrug-resistant bacterial infections and rare diseases. This page serves as the definitive source for verified news and official updates on SPRO's research advancements, regulatory milestones, and strategic initiatives.

Investors and healthcare professionals will find timely updates on key programs including tebipenem HBr (oral carbapenem antibiotic), SPR206 (IV polymyxin), and other pipeline developments. The curated news collection covers clinical trial results, FDA communications, partnership announcements, and financial disclosures.

All content is rigorously verified to ensure accuracy and relevance for stakeholders monitoring antibiotic innovation. Bookmark this page for direct access to SPRO's latest developments in addressing critical unmet medical needs through advanced therapeutic candidates.

Rhea-AI Summary

Spero Therapeutics (SPRO) announced its Q4 and full-year 2024 financial results, reporting a net loss of $(20.9) million for Q4 and $(68.6) million for the full year. Total revenue decreased to $15.0 million in Q4 2024 from $73.5 million in Q4 2023.

Key pipeline updates include:

  • Pre-specified interim analysis of Phase 3 PIVOT-PO trial for tebipenem HBr in complicated urinary tract infection expected in Q2 2025
  • SPR720 program for NTM-PD under review following missed primary endpoint in Phase 2 study
  • SPR206 program discontinued after pipeline reprioritization in Q1 2025

The company's cash position stands at $52.9 million, with runway extending into Q2 2026, supported by GSK milestone payments. Leadership changes include Esther Rajavelu's appointment as Interim CEO following a SEC Wells Notice related to certain public disclosures from March-May 2022.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.88%
Tags
-
Rhea-AI Summary

Spero Therapeutics (SPRO), a multi-asset clinical-stage biopharmaceutical company focused on rare diseases and multi-drug resistant bacterial infections, has scheduled its Fourth Quarter and Full Year 2024 financial results announcement for March 27, 2025.

The company will host a conference call and audio webcast at 4:30 p.m. ET to discuss results and provide business updates. Investors can access the call via domestic (1-844-825-9789) or international (1-412-317-5180) dial-in numbers using conference ID 10196669.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.4%
Tags
conferences earnings
-
Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO), a clinical-stage biopharmaceutical company specializing in rare diseases and multi-drug resistant bacterial infections treatments, has announced its participation in the TD Cowen 45th Annual Health Care Conference.

The conference will take place in Boston from March 3rd to 5th, 2025, where Esther Rajavelu, Spero's Interim President and CEO, will present and be available for one-on-one meetings. Interested parties can access the presentation webcast through Spero Therapeutics' website under the 'Events and Presentations' section, with a replay available after the event.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
conferences
Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on developing treatments for rare diseases and multi-drug resistant bacterial infections, has announced its participation in the TD Cowen 45th Annual Health Care Conference.

The conference will be held in Boston from March 3-5, 2025, where Esther Rajavelu, Spero's Interim President and CEO, will present and be available for one-on-one meetings with interested parties.

Those interested in scheduling meetings can contact their institutional representative or email for details. A webcast of the presentation will be accessible through Spero Therapeutics' website on the "Events and Presentations" page under the "Connect" tab, with a replay available after the event concludes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.93%
Tags
conferences
-
Rhea-AI Summary

Spero Therapeutics (SPRO) announced interim leadership changes in response to an SEC Wells Notice regarding certain public disclosures made in 2022. Esther Rajavelu has been appointed Interim President and CEO, replacing Sath Shukla who has taken voluntary paid administrative leave. Frank Thomas has been appointed Chairman of the Board, replacing Dr. Ankit Mahadevia.

The company reported that its Phase 3 PIVOT-PO trial of Tebipenem HBr has reached over 60% enrollment as of December 31, 2024, and remains on track for completion in 2H 2025. The trial aims to enroll approximately 2,648 participants for testing this oral carbapenem antibiotic for complicated urinary tract infections.

Spero reported $52.9 million in cash and cash equivalents (unaudited) as of December 31, 2024, maintaining its cash runway guidance into mid-2026. The company's SPR720 Phase 2a trial did not meet its primary endpoint, with safety concerns noted at the 1,000mg dose level.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2%
Tags
management
-
Rhea-AI Summary

Spero Therapeutics (SPRO) reported Q3 2024 financial results with a net loss of $17.1 million ($0.32 per share), compared to $3.2 million loss in Q3 2023. Revenue decreased to $13.5 million from $25.5 million year-over-year. The company's Phase 3 PIVOT-PO trial for tebipenem HBr remains on track for enrollment completion in 2H 2025. Following SPR720 development suspension and a 39% workforce reduction, cash position stands at $76.3 million, extending runway into mid-2026. R&D expenses increased to $26.9 million from $16.4 million, while G&A expenses decreased to $5.2 million from $5.7 million year-over-year.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.6%
Tags
Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO), a clinical-stage biopharmaceutical company specializing in treatments for rare diseases and multi-drug resistant bacterial infections, announced it will release its third quarter 2024 financial results on Thursday, November 14, 2024, after the market close. The company will also provide a business update at that time. Notably, Spero Therapeutics will not host a conference call to discuss the results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.76%
Tags
conferences earnings
-
Rhea-AI Summary

Spero Therapeutics announced that its Phase 2a study of SPR720 for Nontuberculous Mycobacterial Pulmonary Disease failed to meet its primary endpoint. The interim analysis showed antimicrobial activity but insufficient separation from placebo, with safety concerns including three cases of reversible grade 3 hepatotoxicity. The company is suspending the SPR720 program and implementing a 39% workforce reduction.

The company reported an unaudited Q3 2024 cash balance of $76.3 million, with runway extended into mid-2026. The Phase 3 PIVOT-PO trial of tebipenem HBr remains on track for completion in 2H 2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
-
Rhea-AI Summary

Spero Therapeutics announced a poster presentation at IDWeek 2024 showcasing in vitro data on SPR719, the active moiety of SPR720, for treating nontuberculous mycobacterium pulmonary disease (NTM-PD). The study, conducted with Microbiologics, revealed:

1. SPR719's low propensity for resistance development in MAC NTM-PD strains, both alone and combined with standard care antibiotics.

2. High potency against macrolide susceptible and resistant MAC strains.

3. Mutation frequencies about 3 orders of magnitude lower than standard of care comparators.

4. No antagonism when combined with clarithromycin or ethambutol.

These findings highlight SPR720's potential for prolonged combination regimens in NTM-PD treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.63%
Tags
none
Rhea-AI Summary

Spero Therapeutics (Nasdaq: SPRO) has published data from its Phase 1 clinical trial assessing the intrapulmonary pharmacokinetics of SPR719, the active moiety of SPR720, in Antimicrobial Agents and Chemotherapy. The study, involving 33 healthy subjects, showed significant lung uptake and enhanced concentrations of SPR719 in epithelial lining fluid (ELF) and alveolar macrophages (AM).

Key findings include:

  • SPR719 concentrations in ELF and AM were greater than total plasma concentrations
  • No unexpected safety issues were observed
  • Results support further investigation of SPR720 as a potential oral treatment for Non-Tuberculous Mycobacterial Pulmonary Disease (NTM-PD)

The company will present additional data on microbial resistance against SPR719 at IDWeek in October 2024.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.53%
Tags
Spero Therapeuti

Nasdaq:SPRO

SPRO Rankings

SPRO Stock Data

42.16M
41.52M
24.47%
24.89%
0.78%
Biotechnology
Pharmaceutical Preparations
Link
United States
CAMBRIDGE